Agios Pharmaceuticals (AGIO) Scheduled to Post Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.63) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.64) by ($0.08). The company had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. Agios Pharmaceuticals’s revenue for the quarter was up 65.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 EPS. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded up $0.24 during trading hours on Tuesday, hitting $33.00. The stock had a trading volume of 29,504 shares, compared to its average volume of 793,044. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $35.50. The firm has a 50 day simple moving average of $30.24 and a 200-day simple moving average of $25.36.

Insider Activity

In related news, insider James William Burns sold 2,642 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the sale, the insider now directly owns 34,518 shares in the company, valued at approximately $1,124,251.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider James William Burns sold 2,642 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the sale, the insider now owns 34,518 shares of the company’s stock, valued at approximately $1,124,251.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now owns 137,396 shares in the company, valued at $3,785,259.80. The disclosure for this sale can be found here. Insiders have sold 16,035 shares of company stock valued at $475,277 in the last 90 days. Insiders own 4.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AGIO. Royal Bank of Canada decreased their price objective on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. Finally, JPMorgan Chase & Co. dropped their price objective on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research note on Friday, February 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $33.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.